First Time Loading...

Rhythm Pharmaceuticals Inc
NASDAQ:RYTM

Watchlist Manager
Rhythm Pharmaceuticals Inc Logo
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Watchlist
Price: 38.28 USD 0.34% Market Closed
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

RYTM Price Targets Summary
Rhythm Pharmaceuticals Inc

Wall Street analysts forecast RYTM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RYTM is 60.07 USD with a low forecast of 49.49 USD and a high forecast of 84 USD.

RYTM Lowest Forecast
Wall Street Target
49.49 USD
29% Upside
RYTM Average Forecast
Wall Street Target
60.07 USD
57% Upside
RYTM Highest Forecast
Wall Street Target
84 USD
119% Upside
Lowest
Price Target
49.49 USD
29% Upside
Average
Price Target
60.07 USD
57% Upside
Highest
Price Target
84 USD
119% Upside
Rhythm Pharmaceuticals Inc Competitors:
Price Targets
SOBI
Swedish Orphan Biovitrum AB (publ)
23% Upside
HPHA
Heidelberg Pharma AG
288% Upside
T
1875
TOT BIOPHARM International Co Ltd
131% Upside
BVXP
Bioventix PLC
35% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
23% Upside
HPHA
Heidelberg Pharma AG
288% Upside
T
1875
TOT BIOPHARM International Co Ltd
131% Upside
BVXP
Bioventix PLC
35% Upside
CYTK
Cytokinetics Inc
48% Upside
H
145020
Hugel Inc
2% Upside
X
688278
Xiamen Amoytop Biotech Co Ltd
18% Downside
VYGR
Voyager Therapeutics Inc
138% Upside

Revenue
Forecast

Revenue Estimate
Rhythm Pharmaceuticals Inc

The compound annual growth rate of Rhythm Pharmaceuticals Inc's revenue for the next 3 years is 70%.

N/A
Past Growth
70%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Rhythm Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Rhythm Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
What are analyst estimates?

See Also

Summary
RYTM intrinsic value, competitors valuation, and company profile.
DCF Valuation
RYTM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RYTM stock valuation using valuation multiples.
Wall Street Estimates
RYTM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RYTM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RYTM's stock price target?
Price Target
60.07 USD

According to Wall Street analysts, the average 1-year price target for RYTM is 60.07 USD with a low forecast of 49.49 USD and a high forecast of 84 USD.

What is Rhythm Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
70%

The compound annual growth rate of Rhythm Pharmaceuticals Inc's revenue for the next 3 years is 70%.

ALPHA SPREAD
Join more than 132,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.